6.90
-0.15(-2.13%)
Currency In USD
| Previous Close | 7.05 |
| Open | 6.88 |
| Day High | 7.5 |
| Day Low | 6.76 |
| 52-Week High | 22.5 |
| 52-Week Low | 6.17 |
| Volume | 215,228 |
| Average Volume | 267,473 |
| Market Cap | 410.3M |
| PE | -1.91 |
| EPS | -3.61 |
| Moving Average 50 Days | 12.29 |
| Moving Average 200 Days | 10.59 |
| Change | -0.15 |
If you invested $1000 in IGM Biosciences, Inc. (IGMS) since IPO date, it would be worth $283.95 as of December 21, 2024 at a share price of $6.9. Whereas If you bought $1000 worth of IGM Biosciences, Inc. (IGMS) shares 3 years ago, it would be worth $243.99 as of December 21, 2024 at a share price of $6.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 08, 2024 12:00 PM GMT
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by yea
IGM Biosciences to Present at Three Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2024 12:00 PM GMT
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
GlobeNewswire Inc.
Sep 30, 2024 8:01 PM GMT
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Offi